AbbVie's lutikizumab clears late-stage test in painful skin disease

AbbVie (ABBV) said its drug lutikizumab hit the main goal of a Phase 3 trial in hidradenitis suppurativa, a chronic, painful skin condition, with 31% of patients responding versus 23% on placebo. The company plans to start testing the drug in a weight-loss combination by year-end. John Hickenlooper holds the stock.

Sources

AbbVie's Lutikizumab Meets Goal in Late-Stage Skin Disease Trial, 31% vs 23% on Placebo; Weight-Loss Combination Test Planned by Year-End
The whole story · updated
R
Reuters
·
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in